Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.

N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.


Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.

Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X, Schlienger K, Silber JL.

Vaccine. 2015 Jun 17;33(27):3129-34. doi: 10.1016/j.vaccine.2015.04.090. Epub 2015 May 8.


Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.

Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL.

Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7.


Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.

Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL.

Vaccine. 2010 Jun 7;28(25):4204-9. doi: 10.1016/j.vaccine.2010.04.003. Epub 2010 Apr 21.


Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.

Sutradhar SC, Wang WW, Schlienger K, Stek JE, Xu J, Chan IS, Silber JL.

Clin Vaccine Immunol. 2009 May;16(5):646-52. doi: 10.1128/CVI.00407-08. Epub 2009 Mar 4.


A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, Azrolan N, Sutradhar SC, Wang WW, Chan IS, Schlienger K, Schödel F, Silber JL; Zostavax Protocol 010 Study Group.

Clin Vaccine Immunol. 2008 Feb;15(2):314-9. Epub 2007 Dec 12.


Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.

Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.

J Am Geriatr Soc. 2007 Oct;55(10):1499-507.


Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.

Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, Meechan C, Li D, Schlienger K, Chan I, Sadoff J, Schödel F, Silber JL.

Vaccine. 2007 Mar 1;25(11):2139-44. Epub 2006 Nov 27.


Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.

Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL, Harmon A, Chalikonda I, Smith JG, Stek JE, Robertson A, Caulfield MJ, Biasio LR, Silber JL, Chan CY, Vessey R, Sadoff J, Chan IS, Matthews H, Wang W, Schlienger K, Schödel FP; Protocol 049 Study Group.

Vaccine. 2006 Nov 17;24(47-48):6875-85. Epub 2006 Jul 7.


A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells.

Gutzmer R, Li W, Sutterwala S, Lemos MP, Elizalde JI, Urtishak SL, Behrens EM, Rivers PM, Schlienger K, Laufer TM, Eck SL, Marks MS.

J Immunol. 2004 Jul 15;173(2):1023-32.


Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons.

Bernstein WB, Cox JH, Aronson NE, Tracy L, Schlienger K, Ratto-Kim S, Garner R, Cotte J, Zheng Z, Winestone L, Liebig C, Galley LM, Connors M, Birx DL, Carroll RG, Levine BL.

Clin Immunol. 2004 Jun;111(3):262-74.


Extensive replicative capacity of human central memory T cells.

Maus MV, Kovacs B, Kwok WW, Nepom GT, Schlienger K, Riley JL, Allman D, Finkel TH, June CH.

J Immunol. 2004 Jun 1;172(11):6675-83.


Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.

Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ.

J Infect Dis. 2003 Nov 1;188(9):1336-44. Epub 2003 Oct 17.


Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector.

Varnavski AN, Schlienger K, Bergelson JM, Gao GP, Wilson JM.

Hum Gene Ther. 2003 Apr 10;14(6):533-44.


TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.

Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH.

Clin Cancer Res. 2003 Apr;9(4):1517-27.


Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.

Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G.

Clin Cancer Res. 2003 Jan;9(1):264-72.


Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G.

N Engl J Med. 2003 Jan 16;348(3):203-13.


Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH.

J Immunol. 2002 May 1;168(9):4272-6.


Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients.

Chu CS, Woo EY, Toll AJ, Rubin SC, June CH, Carroll RG, Schlienger K.

Clin Immunol. 2002 Mar;102(3):291-301.


Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH.

Nat Biotechnol. 2002 Feb;20(2):143-8.


Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, Humphries MJ, Ratto-Kim S, Birx DL, Steffens C, Landay A, Carroll RG, June CH.

Nat Med. 2002 Jan;8(1):47-53.


Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.

Cancer Res. 2001 Jun 15;61(12):4766-72.


Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells.

Schlienger K, Craighead N, Lee KP, Levine BL, June CH.

Blood. 2000 Nov 15;96(10):3490-8.


A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy.

Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, Miller A, Brightbill H, Schlienger K, Rea TH, Modlin RL.

J Immunol. 2000 Aug 1;165(3):1506-12.


Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule.

Riley JL, Schlienger K, Blair PJ, Carreno B, Craighead N, Kim D, Carroll RG, June CH.

J Exp Med. 2000 Jun 5;191(11):1987-97.


B7-1, but not CD28, is crucial for the maintenance of the CD4+ T cell responses in human leprosy.

Schlienger K, Uyemura K, Jullien D, Sieling PA, Rea TH, Linsley PS, Modlin RL.

J Immunol. 1998 Sep 1;161(5):2407-13.


Immunogenicity of hybrid hepatitis B surface antigen particles.

Mancini M, Schlienger K, Tiollais P, Michel ML.

Int Rev Immunol. 1994;11(2):143-51. Review.


Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes.

Michel ML, Mancini M, Schlienger K, Tiollais P.

Res Virol. 1993 Jul-Aug;144(4):263-7.


Supplemental Content

Loading ...
Support Center